Assessment of recombinant factor VIIa as an antidote for bleeding induced in the rabbit by low molecular weight heparin

Journal of Thrombosis and Haemostasis

Volumn 1, Issue 4, 2003, Pages 760-765

  Chan, S ^a,b   Kong, M ^a   Minning, D M ^a   Hedner, U ^c   Marder, V J ^a,b  

^a Los Angeles Orthopaedic Hospital   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Novo Nordisk Scandinavia   (Sweden)

Author keywords

Bleeding; Low molecular weight heparin; Rabbits; Recombinant factor VIIa

Indexed keywords

ANTIDOTE; BLOOD CLOTTING FACTOR 7; LOW MOLECULAR WEIGHT HEPARIN; RECOMBINANT FVIIA; RECOMBINANT PROTEIN; TINZAPARIN;

ANIMAL; ARTICLE; BLEEDING; BLEEDING TIME; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; DRUG SCREENING; HEMOSTASIS; KINETICS; MALE; RABBIT;

ANIMALS; ANTIDOTES; BLEEDING TIME; DRUG EVALUATION; FACTOR VII; HEMORRHAGE; HEMOSTASIS; HEPARIN, LOW-MOLECULAR-WEIGHT; KINETICS; MALE; RABBITS; RECOMBINANT PROTEINS;

EID: 0142228257     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1046/j.1538-7836.2003.00101.x     Document Type: Article

References (21)

1. Ginsberg JS, Hirsh J. Treatment of venous thromboembolism. In: Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Lippincott, Williams & Wilkins, 2001: pp. 1405-12.
2. Diness VO, Ostergaard PB. Neutralization of a low-molecular weight heparin (LHN-1) and conventional heparin by protamine sulfate in rats. Thromb Haemost 1986; 56: 318-22.
3. Jurlander B, Thim L, Klausen NK, Persson E, Kjalke M, Rexen P, Jorgensen TB, Ostergaard PB, Erhardtsen E, Bjorn SE. Recombinant activated factor VII (rFVIIa): characterization, manufacturing, and clinical development. Semin Thromb Hemost 2001; 27: 373-84.
4. Lusher J, Ingerslev J, Roberts H, Hedner U. Clinical experience with recombinant factor Vila. Blood Coagul Fibrinolysis 1998; 9: 119-28.
5. Kalicinski P, Kalicinski A, Drewniak T, Ismail H, Szymczak M, Markiewicz M, Lukasiewicz H. Quick correction of hemostasis in two patients with fulminant liver failure undergoing liver transplantation by recombinant activated factor VII. Transplant Proc 1999; 31: 378-9.
6. Hendriks HG, Meijer K, de Wolf JT, Klompmaker IJ, Porte RJ, de Kam PJ, Hagenaars AJ, Melsen T, Slooff MJ, van der Meer J. Reduced transfusion requirements by recombinant factor Vila in orthotopic liver transplantation: a pilot study. Transplantation 2001; 15: 402-5.
7. Berntorp E. Recombinant FVIIa in the treatment of warfarin bleeding. Semin Thromb Hemost 2000; 26: 433-5.
8. Monroe DM, Hoffman M, Allen FA, Roberts HR. The factor VII-platelet interplay: effectiveness of recombinant factor Vila in the treatment of bleeding in severe thrombocytopathia. Semin Thromb Hemost 2000; 26: 373-7.
9. Hunault M, Bauer KA. Recombinant factor Vila for the treatment of congenitalfactorVIIdeficiency. Semin Thromb Hemost 2000; 26: 401-5.
10. Marder VJ, Shortell CK, Fitzpatrick PG, Kim C, Oxley D. An animal model of fibrinolytic bleeding based on the rebleed phenomenon: Application to a study of vulnerability of hemostatic plugs of different age. Thromb Res 1992; 67: 31-40.
11. Montoney M, Gardell SJ, Marder VJ. Comparison of the bleeding potential of vampire bat salivary plasminogen activator versus tissue plasminogen activator in an experimental rabbit model. Circulation 1995; 91: 1540-4.11.
12. Bove CM, Casey B, Marder VJ. DDAVP reduces bleeding during continued hirudin administration in the rabbit. Thromb Haemost 1996; 75: 471-5.
13. Teien AN, Lie M. Evaluation of an amidolytic heparin assay method: increased sensitivity by adding purified antithrombin III. Thromb Res 1977; 10: 399-410.
14. Owren PA, Aas K. The control of dicumarol therapy and the quantitative determination of prothrombin and proconvertin. Scand J Clin Lab Invest 1951; 3: 201-7.
15. Lindley CM, Sawyer WT, Macik BG, Lusher J, Harrison JF, Baird-Cox K, Birch K, Glazer S, Roberts HR. Pharmacokinetics and pharmaco-dynamics of recombinant factor Vila. Clin Pharmacol Ther 1994; 55: 638-48.
16. Doutremepuich C, Toulemonde F, Bousquet F, Bonini F. Comparison of the haemorrhagic effects of unfractionated heparin and a low molecular weight heparin fraction (CY 216) in rabbits. Thromb Res 1986; 43: 691-5.
17. Hyers TM, Agnelli G, Hull RD, Morris TA, Samama M, Tapson V, Weg JG. Antithrombotic therapy for venous thromboembolic disease. Chest 2001; 119: S176-93.
18. Galan AM, Tonda R, Altisent C, Maragall S, Ordinas A, Escolar G. Recom-binant factor Vila (Novoseven) restores deficient coagulation: experience from an ex vivo model. Semin Rematol 2001; 38 (Suppl. 12): 10-4.
19. Kjalke M, Monroe DM, Hoffman M, Oliver JA, Ezban M, Hedner U, Roberts HR. The effects of activated factor VII in a cell-based model for tissue factor-initiated coagulation. Blood Coagul Fibrinolysis Suppl 1998; 1: S21-5.
20. Friederich PW, Levi M, Bauer KA, Vlasuk GP, Rote WE, Breederveld D, Keller T, Spataro M, Barzegar S, Buller HR. Ability of recombinant factor Vila to generate thrombin during inhibition of tissue factor in human subjects. Circulation 2001; 103: 2555-9.
21. Hedner U. Recombinant activated factor VII as a universal haemostatic agent. Blood Coagul Fibrinolysis 1999; 10: 521-2.